List of Excipients in Branded Drug ZONISADE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Phramaceuticals Inc	ZONISADE	zonisamide	52652-8001	CARBOXYMETHYLCELLULOSE SODIUM
Azurity Phramaceuticals Inc	ZONISADE	zonisamide	52652-8001	CELLULOSE, MICROCRYSTALLINE
Azurity Phramaceuticals Inc	ZONISADE	zonisamide	52652-8001	CITRIC ACID MONOHYDRATE

ZONISADE Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

ZONISADE is a differentiated oral suspension of zonisamide, an established antiseizure drug historically supplied mainly as capsules. Its commercial opportunity comes from liquid dosing, not from new pharmacology. The strongest excipient strategies are taste masking, physical stability, dose uniformity, preservative optimization, and packaging that supports accurate administration.

The product is ZONISADE (zonisamide) oral suspension, 100 mg/5 mL, approved by the U.S. Food and Drug Administration for adjunctive treatment of partial seizures in adults. The product is associated with Azurity Pharmaceuticals and was approved under NDA 214599 in December 2022. Its liquid presentation addresses patients who cannot reliably swallow capsules and allows dose measurement in smaller increments than fixed-strength capsules. (FDA, 2022)

What excipients are used in ZONISADE?

ZONISADE uses a conventional aqueous suspension system with sweetening, viscosity, preservation, buffering and flavor functions.

Excipient or excipient class	Likely commercial function in ZONISADE
Glycerin	Humectant, mouthfeel modifier and cosolvent
Xanthan gum or comparable suspending polymer	Controls sedimentation and supports redispersibility
Sucralose	Sweetener and bitterness reduction
Flavor system	Improves palatability and supports adherence
Methylparaben	Antimicrobial preservative
Potassium sorbate	Antimicrobial preservation, particularly in an acidic system
Sodium citrate dihydrate	Buffering and pH control
Purified water	Continuous aqueous phase

The FDA prescribing information identifies the product as an oral suspension containing 100 mg of zonisamide per 5 mL. The label also includes handling instructions relevant to suspension performance, including shaking before use and use of a calibrated oral dosing device. (FDA, 2022)

Zonisamide is poorly suited to a simple aqueous solution strategy. A suspension requires control of particle size, wetting, sedimentation, caking, redispersion and dose uniformity throughout the bottle’s shelf life. Excipient selection therefore has direct consequences for product quality and regulatory defensibility.

What excipient functions are most important for ZONISADE?

Taste masking

Zonisamide has a challenging taste profile. Sucralose and flavoring can reduce bitterness, but sweetener-only approaches are unlikely to be sufficient for all patients. Commercially relevant taste-masking options include:

• Higher-efficiency flavor systems that reduce the required sweetener load.
• Polymer-based taste barriers.
• Ion-exchange resins, if they do not compromise release or dose uniformity.
• Cyclodextrin complexes, subject to cost, tolerability and regulatory justification.
• Multiparticulate or coated-particle suspension systems.
• pH optimization that reduces perceived bitterness without reducing chemical stability.

Taste masking is particularly important because the product is intended for repeated administration. A formulation that is acceptable during a single clinical dose may fail under chronic-use conditions.

Suspension stability

The suspending system must keep zonisamide particles evenly distributed after normal storage and transport. The key performance attributes are:

• Sedimentation rate.
• Sediment volume.
• Ease and speed of redispersion.
• Absence of hard cake formation.
• Dose uniformity at the beginning, middle and end of the bottle.
• Viscosity across the storage temperature range.
• Compatibility with oral syringes.

Xanthan gum is commercially attractive because it provides suspension capacity at relatively low concentrations and has broad pharmaceutical use. Its limitations include mouthfeel, stringiness, viscosity drift and potential interaction with flavor systems. Alternatives such as microcrystalline cellulose with carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose or synthetic acrylic polymers could create opportunities for improved texture and reduced sedimentation.

A replacement suspension system must preserve dose accuracy. Higher viscosity is not automatically better. Excessive viscosity can make oral-syringe withdrawal difficult and can increase residual product in the bottle.

Preservation

ZONISADE uses a multi-component preservation approach involving methylparaben and potassium sorbate, supported by pH control. This strategy is commercially effective but creates several development questions:

• Is the preservative system robust against the applicable antimicrobial effectiveness standard?
• Does preservative concentration remain stable over the full shelf life?
• Does the flavor system alter preservative partitioning?
• Does the bottle or dosing syringe adsorb preservative?
• Are parabens acceptable for the intended patient population and markets?
• Can the product maintain microbiological quality after repeated opening?

A preservative-free version would have commercial appeal, but it would require a credible multidose microbial-control strategy. Options include unit-dose packaging, an air-restrictive closure, a validated dispensing system or a lower-water-activity formulation. Those approaches could raise manufacturing and packaging costs.

pH and chemical stability

Zonisamide stability must be evaluated in the presence of water, buffer, preservatives, flavor components and suspension polymers. The citrate system provides pH control, but pH changes can affect:

• Zonisamide chemical degradation.
• Preservative efficacy.
• Flavor stability.
• Polymer hydration.
• Patient acceptability.
• Container closure compatibility.

A commercially valuable follow-on formulation would need a clear stability advantage, such as a longer in-use period, improved temperature tolerance or reduced preservative dependence.

What formulation patents protect ZONISADE?

ZONISADE is a liquid dosage-form product rather than a new chemical entity. Zonisamide’s core compound protection expired years before the launch of ZONISADE. The relevant intellectual-property value is therefore concentrated in formulation, suspension, dosing and manufacturing claims.

Potential claim categories include:

Claim category	Commercial relevance
Aqueous zonisamide suspension	Protects the basic liquid dosage form
Specific excipient combinations	May limit direct substitution with the same formulation architecture
Concentration and dose volume	Protects a commercially practical strength such as 100 mg/5 mL
Particle-size distribution	Can control suspension behavior and dose uniformity
pH range	May link chemical stability and preservative performance to the claim
Redispersibility or sedimentation limits	Can protect performance rather than ingredients alone
Packaging and dosing device	May protect the commercial delivery system
Method of treating seizures with the suspension	May support method-of-use protection
Manufacturing process	Can cover milling, wetting, homogenization or order of addition

Exact patent numbers, claims, expiration dates and Orange Book status must be determined from the current FDA Orange Book and U.S. Patent and Trademark Office records. Patentability is strongest when the formulation demonstrates an unexpected technical result, such as superior redispersion, improved dose uniformity, reduced degradation or clinically meaningful taste improvement. A patent that only recites a routine combination of known sweeteners, preservatives and suspending agents is more vulnerable to obviousness challenges.

When does ZONISADE lose exclusivity?

ZONISADE was approved in December 2022. As a new dosage form of an existing active ingredient, the product could qualify for three years of approval-related exclusivity under the Federal Food, Drug, and Cosmetic Act if the application contained new clinical investigations essential to approval. On that basis, the principal statutory exclusivity period would generally run to December 2025. (FDA, 2023)

Three-year exclusivity does not block all competing products. It blocks FDA approval of certain applications that rely on the same new clinical investigations, but it does not prevent all patent challenges or all alternative zonisamide products.

Protection type	Relevance to ZONISADE
New chemical entity exclusivity	Not expected because zonisamide was previously approved
Three-year exclusivity	Potentially relevant to the new oral suspension approval
Orphan-drug exclusivity	Not indicated for the broad adult partial-seizure indication
Patent protection	Depends on live formulation, method and manufacturing claims
Pediatric exclusivity	Could add six months if an eligible written request was completed
Trade-secret protection	Relevant to flavor composition, process parameters and supplier specifications

The practical generic-entry date depends on the intersection of statutory exclusivity, patent certifications, FDA application timing and litigation. An ANDA applicant could pursue a Paragraph IV certification against listed patents or a Paragraph III certification to await expiry.

What is the Orange Book status of ZONISADE?

The FDA Orange Book is the controlling source for listed patents and exclusivity associated with NDA 214599. The relevant review should cover:

• NDA 214599.
• ZONISADE as the reference listed drug.
• Listed formulation patents.
• Listed method-of-use patents.
• Patent expiration dates.
• Pediatric exclusivity, if any.
• Whether a listed patent is eligible for a Paragraph IV certification.

A product-specific excipient strategy should not assume that every formulation patent blocks every alternative suspension. A competitor may design around a claim by changing:

• The suspending polymer.
• The preservative system.
• The pH range.
• The particle-size distribution.
• The concentration.
• The packaging configuration.
• The flavoring composition.
• The manufacturing sequence.

The legal exposure is highest where claims cover broad combinations such as “zonisamide in an aqueous oral suspension” and lower where claims require narrow excipient concentrations or tightly defined process parameters.

Which companies are challenging ZONISADE?

The generic competitive field includes established manufacturers of zonisamide capsules and companies that develop liquid products through the ANDA or 505(b)(2) pathways. Capsule manufacturers have an immediate active-ingredient supply chain but do not automatically have a substitutable liquid product.

A liquid competitor could pursue:

1. An ANDA referencing ZONISADE, if the dosage form and regulatory requirements support that pathway.
2. A 505(b)(2) application with a distinct formulation, dosing device or clinical presentation.
3. A compounded or pharmacy-prepared suspension, which is commercially relevant but not equivalent to an FDA-approved product.
4. A private-label or licensing arrangement using a contract development and manufacturing organization.

The principal barriers are formulation reproducibility, taste, microbial control, suspension uniformity and regulatory documentation. Zonisamide is not protected by biologic complexity, so biosimilar risk is not relevant. The relevant threat is generic and reformulated-generic competition.

What commercial opportunities exist for ZONISADE excipients?

Pediatric and dysphagia-focused liquid formulations

The current labeled indication is for adults, but the liquid format has practical value for patients with dysphagia, feeding tubes or difficulty taking capsules. A formulation optimized for pediatric or enteral administration could support a new development program, subject to clinical and regulatory requirements.

Commercial opportunities include:

• Lower-volume dosing at higher concentration.
• Tube-compatible suspension behavior.
• Reduced clogging risk.
• Improved syringe withdrawal.
• Low-sugar or sugar-free presentation.
• Better taste after dilution.
• Unit-dose packaging for institutional use.

Premium preservative-free presentation

A preservative-free version could command a premium in hospitals, specialty pharmacies and patients with preservative sensitivity. The commercial model would likely depend on packaging economics. Unit-dose cups, sachets or closed dispensing systems would increase cost but could reduce microbial risk and simplify in-use dating.

Improved dosing technology

A bottle-and-syringe system can be differentiated through:

• Dose markings matched to common zonisamide regimens.
• Low-residual-volume syringes.
• Adapters that reduce spillage.
• Child-resistant, senior-friendly closures.
• Bottle geometry that improves suspension recovery.
• Device instructions that reduce underdosing after inadequate shaking.

Device claims may provide a separate intellectual-property layer from the excipient formulation.

Global formulation adaptation

Excipient acceptability varies by jurisdiction. Parabens, flavors, colorants and certain polymers can face different regulatory expectations across the United States, Europe, Japan and emerging markets. A global formulation platform should prioritize:

• Excipients with broad compendial acceptance.
• Low allergen and low sensitization profiles.
• Stable supply from multiple qualified vendors.
• Clear impurity and elemental-risk packages.
• Compatibility with local labeling and dosing devices.

How strong is the ZONISADE patent estate?

The estate is likely strongest where it combines a practical liquid dosage form with demonstrated performance data. The most defensible formulation patents would show that the selected excipient system solves a specific zonisamide problem, such as poor wetting, unacceptable taste, rapid settling or preservative instability.

Patent strength is weaker for claims based solely on routine formulation choices. A competitor can challenge such claims using prior-art oral suspensions, standard suspending agents, known sweeteners and conventional preservative systems.

Patent-strength factor	Assessment
New active ingredient	Low
New liquid presentation	Moderate
Specific excipient system	Moderate, depending on claim breadth
Demonstrated unexpected stability or palatability	Stronger
Dosing-device integration	Moderate
Manufacturing know-how	Potentially strong as a trade secret
Biosimilar barrier	Not applicable
Generic design-around risk	Material

What litigation and settlement risks affect ZONISADE?

The most likely disputes would involve Paragraph IV challenges to listed formulation or method patents. A patent owner could seek a 30-month stay after receiving notice of a Paragraph IV certification, provided the statutory conditions are met. The commercial result could be:

• Delayed generic approval.
• Early launch under a settlement agreement.
• A license with a negotiated entry date.
• A dismissal after narrowing or removing patent claims.
• At-risk launch followed by damages exposure.

Settlement analysis should focus on the earliest licensed entry date, authorized-generic rights, formulation restrictions and whether the agreement includes a supply or co-development arrangement. Public litigation records, FDA Orange Book updates and SEC disclosures from publicly traded participants are the relevant evidence sources.

What generic launch scenarios exist for ZONISADE?

The principal scenarios are:

Scenario	Expected market effect
No listed patent barrier after exclusivity	Rapid price competition from a liquid generic
Paragraph IV litigation with settlement	Delayed but defined generic entry
Narrow formulation patent survives	Capsule generics remain weak substitutes for the liquid product
Successful design-around	Competitor launches a different suspension architecture
505(b)(2) reformulation	Premium or differentiated liquid product without exact duplication
Pharmacy compounding growth	Limited substitution, variable quality and lower brand protection

The highest commercial risk is a liquid product that matches ZONISADE’s concentration, flavor acceptability and dosing device while avoiding its narrow formulation claims. Capsule generics are less threatening where patients depend on liquid administration.

Key Takeaways

• ZONISADE’s commercial differentiation is its zonisamide oral suspension, not the active ingredient.
• The most valuable excipient functions are taste masking, suspension uniformity, preservation and syringe compatibility.
• Zonisamide compound protection is no longer the central barrier to competition.
• Product protection is likely concentrated in formulation, manufacturing, dosing and method-of-use claims.
• The potential three-year approval-related exclusivity period points to December 2025 as a key regulatory date, subject to the FDA’s official records.
• Preservative-free, pediatric-oriented, tube-compatible and improved-device versions are the clearest commercial opportunities.
• Generic and 505(b)(2) competition present meaningful risks; biosimilar risk does not apply.
• A strong patent position requires evidence of unexpected formulation performance rather than a routine excipient list.

FAQs About ZONISADE Excipient and Formulation Opportunities

Can ZONISADE be reformulated without xanthan gum?

Yes. Alternatives may include microcrystalline cellulose-carboxymethylcellulose systems, sodium carboxymethylcellulose, hydroxypropyl methylcellulose or other pharmaceutical suspending agents. The replacement must meet dose-uniformity, redispersion, viscosity, stability and palatability requirements.

Is a sugar-free ZONISADE formulation commercially attractive?

Yes. Sucralose-based or other low-calorie systems may support patients requiring sugar restriction. The formulation must preserve taste masking without increasing aftertaste, viscosity or preservative instability.

Can ZONISADE be administered through a feeding tube?

Administration through feeding tubes requires product-specific compatibility testing. Relevant tests include tube adsorption, clogging, recovery, sedimentation during administration and dose delivery after flushing. Capsule opening and extemporaneous compounding should not be treated as equivalent to an FDA-approved liquid product.

What is the best 505(b)(2) opportunity for zonisamide?

A high-value 505(b)(2) program would combine a differentiated formulation with a clinically meaningful administration advantage, such as preservative-free multidose delivery, improved pediatric acceptability, lower dosing volume or validated enteral-tube performance.

Do excipient changes automatically create a new patentable product?

No. A changed excipient system becomes commercially defensible when it produces a non-obvious formulation and a measurable technical advantage. Routine substitution of one known sweetener, preservative or suspending agent for another may face obviousness challenges.

References

1. U.S. Food and Drug Administration. (2022). ZONISADE (zonisamide) oral suspension prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Reference listed drugs and approved drug products: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Regulatory exclusivity and patent provisions for abbreviated new drug applications. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. United States Pharmacopeia. (2024). General chapter <795>: Pharmaceutical compounding - nonsterile preparations. U.S. Pharmacopeial Convention.